Build status - In Progress

A Randomized Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+) HER2 (-) Breast Cancer

A Randomized Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+) HER2 (-) Breast Cancer
Recruiting
18 years - 99 years
All
Phase 3
500 participants needed
1 Location

Brief description of study

The purpose of the study is to evaluate whether SAR439859 (an experimental hormonal treatment), in combination with palbociclib is a better option compared to letrozole (a standard hormonal treatment), in combination with palbociclib, in terms of efficacy and tolerance for treating patients with ER (+), HER2 (-) breast cancer. Eligible patients will be those with patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cancer, Breast Cancer
  • Age: 18 years - 99 years
  • Gender: All

Male or Female Age 18 or older Diagnosis of Breast Cancer

Updated on 04 Aug 2024. Study ID: 849538

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center